Sort   by:  
 Page size 
ProteomicsExtracellular vesicle-associated transcriptomic and proteomic biomarkers show in vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer
Background: Anaplastic thyroid cancer (ATC) is an aggressive and rare disease. Rapid metastasis and limited promising treatments call for additional therapeutic options, including drug repurposing. The early spreading of ATC highlights the importance of rapid therapy success assessment, which could ...
ORGANISM(S): Homo sapiens (Human) 
2025-09-09 | PXD064007 | Pride
Anaplastic thyroid cancer Vandetanib Extracellular vesicles Dose-dependent transcriptomics and proteomics 
GenomicsRNA sequencing on liver samples from wild type C57BL/6J mice exposed to the vandetanib
RNA sequencing on liver samples from wild type C57BL/6J mice exposed to the vandetanib
PRJNA1200011 | ENA
TranscriptomicsRNA sequencing on liver samples from wild type C57BL/6J mice exposed to the vandetanib
Purpose: The aim of this study was to demonstrate the hepatotoxicity mechanism induced by vandetanib. Methods: Liver mRNA profiles of C57BL/6J mice exposed to the vandetanib were generated by RNA sequencing. Results: We analyzed the results of high-throughput transcriptome sequencing on liver sample...
ORGANISM(S): Mus musculus 
2025-12-18 | GSE284661 | GEO
GenomicsDifferentially expressed genes analysis of wild type K562 cells treated with vandetanib and control (DMSO)
Differentially expressed genes analysis of wild type K562 cells treated with vandetanib and control (DMSO)
PRJNA665502 | ENA
TranscriptomicsDifferentially expressed genes analysis of wild type K562 cells treated with vandetanib and control (DMSO)
Purpose: The aim of this study was to evaluate the difference of mRNA and lncRNA in K562 cells treated with vandetanib (1.56 μM) and control (DMSO) by high-throughput sequencing results. Methods: Total RNA was extracted using the RNAfast200 kit according to the manufacturer’s protocol. Then, 200 ng ...
ORGANISM(S): Homo sapiens 
2020-09-25 | GSE158518 | GEO
ClinicalClinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.
2125601 | ecrin-mdr-crc
UnknownRadiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib.
Not available
S-EPMC7408860 | biostudies-literature
GenomicsExtracellular vesicle-associated transcriptomic and proteomic biomarkers show in-vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer
Extracellular vesicle-associated transcriptomic and proteomic biomarkers show in-vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer
PRJEB88458 | ENA
UnknownLong-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.
Not available
S-EPMC6543457 | biostudies-literature
UnknownEffect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer.
Not available
S-EPMC5091223 | biostudies-literature
Sort   by:  
 Page size